14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Gabexate mesylate in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis update.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP), and the benefit of pharmacologic treatment of the condition is unclear. Although prophylactic use of gabexate mesylate (GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncertainty remains regarding the effectiveness of GM treatment in post-ERCP pancreatitis (PEP).

          Related collections

          Author and article information

          Journal
          Curr Ther Res Clin Exp
          Current therapeutic research, clinical and experimental
          Elsevier BV
          0011-393X
          0011-393X
          Aug 2008
          : 69
          : 4
          Affiliations
          [1 ] Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.
          [2 ] Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
          [3 ] Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
          Article
          S0011-393X(08)00077-5
          10.1016/j.curtheres.2008.08.001
          3969935
          24692807
          51b23ed0-7982-44d4-8368-24fda55f44c8
          History

          meta-analysis,gabexate mesylate,randomized controlled trial,prevention,post-endoscopic retrograde cholangiopancreatography pancreatitis

          Comments

          Comment on this article